Buprenorphine Disposition and Clinical Effects



Status:Recruiting
Conditions:Healthy Studies
Therapuetic Areas:Other
Healthy:No
Age Range:18 - 50
Updated:12/15/2017
Start Date:June 2010
End Date:December 2017
Contact:Kristi Kraus
Email:krausk@anest.wustl.edu
Phone:314-747-0421

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

Influence of CYP3A Modulation on Buprenorphine Disposition and Clinical Effects

The purpose of this study is to determine how people absorb and break down (metabolize) and
eliminate buprenorphine and if CYP3A is involved.


Inclusion Criteria:

Each subject must meet all of the following criteria:

1. Male or non-pregnant female volunteer, 18-50 yr old

2. Good general health with no known major medical conditions

3. BMI between 20-33

4. Provide informed consent

Exclusion Criteria:

Subjects will not be enrolled if any of the following criteria exist:

1. Known history of liver or kidney disease

2. Use of prescription or non-prescription medications, herbals or foods known to be
metabolized by or affect CYP3A activity (this includes the use of oral
contraceptives).

3. Females who are pregnant or nursing

4. Known history of drug or alcohol addiction (prior or present addiction or addiction
treatment)

5. Direct physical access to and routine handling of addicting drugs in the regular
course of duty (this is a routine exclusion from studies of drugs with addiction
potential)
We found this trial at
1
site
Washington University School of Medicine
660 S Euclid Ave
Saint Louis, Missouri 63110
(314) 362-5000
Phone: 314-747-1663
Washington University School of Medicine Washington University Physicians is the clinical practice of the School...
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials